Wyeth unveils seven late-stage drugs for 11 indications at its annual R&D presentation
US drug major Wyeth showcased a robust pipeline of late-stage drug candidates, as well as several early-stage compounds, at its annual R&D presentation day for analysts and investors, held in New York this month.
The New Jersey-based pharmaceutical giant, which was the world's tenth largest drugmaker by sales in 2005, highlighted seven new drugs and 11 indications in late-stage clinical development, including new products spanning a variety of therapeutic areas, notably women's health, vaccines and neuroscience.
The firm's chief executive, Robert Essner, said: "we believe these new treatments will help continue the strong growth generated by our broad portfolio led by Enbrel [etanercept; for rheumatoid arthritis] and the pneumococcal disease vaccine Prevnar and could potentially be among Wyeth's top products by 2010."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze